Online inquiry

IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1447MR)

This product GTTS-WQ1447MR is a type of mRNA modified with 5-Methoxy-UTP, which ecodes the monoclonal antibody that targets Aβ15-42 gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Corynebacterium diphtheriae; Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ1447MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13831MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-10987
GTTS-WQ3115MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA APN311
GTTS-WQ10555MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY­3074828
GTTS-WQ13168MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04518600
GTTS-WQ9877MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA KB001-A
GTTS-WQ14504MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RYI-018
GTTS-WQ8672MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ7653MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GEN-1029
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW